Comments
Loading...
Inhibikase Therapeutics (IKT) Forecast
NewsEarningsInhibikase Therapeutics (IKT) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestInhibikase Therapeutics (NASDAQ:IKT) Stock Quotes, Forecast and News Summary
Inhibikase Therapeutics Stock (NASDAQ: IKT) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Inhibikase Therapeutics (IKT) stock?
You can purchase shares of Inhibikase Therapeutics (NASDAQ:IKT) through any online brokerage.
Who are Inhibikase Therapeutics (IKT) competitors?
Other companies in Inhibikase Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), 4D Molecular Therapeutics (NASDAQ:FDMT), Larimar Therapeutics (NASDAQ:LRMR), Neurogene (NASDAQ:NGNE) and Genfit (NASDAQ:GNFT).
What is the forecast, or price target, for Inhibikase Therapeutics (IKT) stock?
Inhibikase Therapeutics has a consensus price target of $6.50.
What is the current price for Inhibikase Therapeutics (IKT)?
The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $2.7606 last updated January 24, 2025 at 2:29 PM EST.
Does Inhibikase Therapeutics (IKT) pay a dividend?
There are no upcoming dividends for Inhibikase Therapeutics.
When is Inhibikase Therapeutics (NASDAQ:IKT) reporting earnings?
Inhibikase Therapeutics’s Q4 earnings are confirmed for Wednesday, March 26, 2025.
Is Inhibikase Therapeutics (IKT) going to split?
There is no upcoming split for Inhibikase Therapeutics.
What sector and industry does Inhibikase Therapeutics (IKT) operate in?
Inhibikase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.